Single-Nucleotide Polymorphisms in MICA and MICB Genes Could Play a Role in the Outcome in AML Patients after HSCT

Show simple item record
dc.contributor.authorMachuldová, Alena
dc.contributor.authorHoudová, Lucie
dc.contributor.authorKratochvílová, Kateřina
dc.contributor.authorLeba, Martin
dc.contributor.authorJindra, Pavel
dc.contributor.authorOstašov, Pavel
dc.contributor.authorMacečková, Diana
dc.contributor.authorKlieber, Robin
dc.contributor.authorGmucová, Hana
dc.contributor.authorŠrámek, Jiří
dc.contributor.authorHolubová, Monika
dc.date.accessioned2022-02-28T11:00:22Z
dc.date.available2022-02-28T11:00:22Z
dc.date.issued2021
dc.description.abstract-translatedNKG2D and its ligands, MICA and MICB, are known as the key regulators of NK cells. NK cells are the first reconstituted cells after the allogeneic hematopoietic stem cell transplantation (HSCT); therefore, it is crucial to understand their role in HSCT outcome. In the presented study, we investigated the single amino acid changes across the exons 2–4 of MICA and MICB genes, and point mutations within the NKG2D gene, which defines the type of NKG2D haploblock (HNK/LNK) in the donors (n = 124), as well as in patients with acute myeloid leukemia (n = 78). In our cohort, we found that graft from a donor with at least one MICA allele containing glycine at position 14 (MICA-14Gly) is significantly associated with deterioration of a patient’s overall survival (OS) (p < 0.05). We also observed a negative effect of MICB-58 (Lys → Glu) polymorphism on relapse-free survival (RFS), although it was not statistically significant in multivariate analysis (p = 0.069). To our knowledge, this is the first work describing the role of MICA-14 and MICB-58 polymorphisms on HSCT outcome.en
dc.format16 s.cs
dc.format.mimetypeapplication/pdf
dc.identifier.citationMACHULDOVÁ, A. HOUDOVÁ, L. KRATOCHVÍLOVÁ, K. LEBA, M. JINDRA, P. OSTAŠOV, P. MACEČKOVÁ, D. KLIEBER, R. GMUCOVÁ, H. ŠRÁMEK, J. HOLUBOVÁ, M. Single-Nucleotide Polymorphisms in MICA and MICB Genes Could Play a Role in the Outcome in AML Patients after HSCT. Journal of Clinical Medicine, 2021, roč. 10, č. 20, s. 1-16. ISSN: 2077-0383cs
dc.identifier.document-number716122700001
dc.identifier.doi10.3390/jcm10204636
dc.identifier.issn2077-0383
dc.identifier.obd43933799
dc.identifier.uri2-s2.0-85116620392
dc.identifier.urihttp://hdl.handle.net/11025/47012
dc.language.isoenen
dc.project.IDNV18-03-00277/Míra polymorfizmů v NK receptorech a jejich ligandech v rámci české populacecs
dc.publisherMDPIen
dc.relation.ispartofseriesJournal of Clinical Medicineen
dc.rights© authorsen
dc.rights.accessopenAccessen
dc.subject.translatedallogeneic hematopoietic cell transplantationgraft-versus-host diseasegraft-versus-tumor effectNKG2DMICAMICBNK cellsen
dc.titleSingle-Nucleotide Polymorphisms in MICA and MICB Genes Could Play a Role in the Outcome in AML Patients after HSCTen
dc.typečlánekcs
dc.typearticleen
dc.type.statusPeer-revieweden
dc.type.versionpublishedVersionen

Files

Collections

OBD
 Articles (NTIS)